IO Biotech (IOBT) Expected to Announce Quarterly Earnings on Wednesday

IO Biotech (NASDAQ:IOBT) is expected to post its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.2133) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

IO Biotech Stock Performance

Shares of IOBT stock opened at $0.33 on Wednesday. The firm has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.88. The stock has a market capitalization of $23.96 million, a PE ratio of -0.25 and a beta of 0.46. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 18.29. IO Biotech has a 52 week low of $0.21 and a 52 week high of $2.79.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IOBT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of IO Biotech in a report on Monday, December 29th. Piper Sandler downgraded IO Biotech from an “overweight” rating to a “neutral” rating in a research report on Friday, January 23rd. Wall Street Zen raised shares of IO Biotech from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Morgan Stanley cut shares of IO Biotech from an “equal weight” rating to an “underweight” rating in a report on Thursday, January 8th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, IO Biotech presently has a consensus rating of “Reduce” and an average price target of $6.33.

Institutional Trading of IO Biotech

Several institutional investors have recently modified their holdings of IOBT. Jane Street Group LLC purchased a new position in shares of IO Biotech in the 1st quarter valued at $26,000. NewEdge Advisors LLC acquired a new position in IO Biotech in the second quarter valued at $34,000. Marex Group plc purchased a new position in shares of IO Biotech during the second quarter worth about $63,000. Boothbay Fund Management LLC acquired a new stake in shares of IO Biotech during the third quarter worth about $215,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in shares of IO Biotech in the 4th quarter valued at about $308,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.

About IO Biotech

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma.